SBC Medical Group (NASDAQ:SBC) & Oncology Institute (NASDAQ:TOI) Head-To-Head Contrast

Oncology Institute (NASDAQ:TOI) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by insiders. Comparatively, 63.9% of SBC Medical Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Oncology Institute has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500.

Earnings and Valuation

This table compares Oncology Institute and SBC Medical Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$378.93 million	0.04	-$83.07 million	($0.78)	-0.27
SBC Medical Group	$223.34 million	2.91	$340,000.00	N/A	N/A

SBC Medical Group has lower revenue, but higher earnings than Oncology Institute.

Profitability

This table compares Oncology Institute and SBC Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-17.63%	-186.83%	-34.58%
SBC Medical Group	N/A	-11.59%	-7.05%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Oncology Institute and SBC Medical Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	0	0	1	0	3.00
SBC Medical Group	0	0	0	0	0.00

Oncology Institute currently has a consensus target price of $2.50, suggesting a potential upside of 1,108.31%. Given Oncology Institute’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Oncology Institute is more favorable than SBC Medical Group.

Summary

SBC Medical Group beats Oncology Institute on 7 of the 12 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.